| INTRODUCTION
In this study, we evaluated the highly sensitive Lumipulse
HBsAg-HQ (HBsAg-HQ) assay (Fujirebio Inc., Tokyo, Japan), which consists of a pretreatment solution for sample disruption and monoclonal antibodies against inner and outer epitopes of the HBsAg molecule. [4] [5] [6] [7] [8] We evaluated the assay with regard to viral mutations, because studies have shown that mutations in the HBsAg gene that are located near the major "a" determinant or in the regulatory elements of surface genes may affect the antigenic profiles of hepatitis B viruses.
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| MATERIAL AND METHODS
| Lumipulse HBsAg-HQ reagents
Monoclonal antibodies against the inner and outer portions of 
| Specimens and panels
This study was approved by the Institutional Review Board of the Osaka University School of Medicine. Serum samples for the evaluation of assay reagents were obtained from hospitalized patients or outpatients at the Osaka University Hospital (the tenets of the Declaration of Helsinki were observed and the study had the approval of the Internal Review Board). Serum samples were collected from 102 HBV-infected patients, who were determined to be HBV carriers and also were positive for other markers of HBV infection or had been undergoing follow-up observations for hepatitis and cirrhosis. Three pooled control panels were prepared using routinely tested serum samples, classified as high, middle, and low concentrations panels.
Commercially available HBsAg seroconversion (PHA935A) and
HBsAg sensitivity (PHA807) panels were purchased from SeraCare Life Science, Inc. (Buffalo, NY, USA). 
| HBsAg variants
| Assay protocol of HBsAg-HQ
The HBsAg-HQ quantitative assay, which is based on an assay reported previously, 5, 8 was used to quantify HBsAg in serum specimens using the automated chemiluminescent enzyme immunoassay instrument (LUMIPULSE G1200; Fujirebio Inc.). 6 This assay system has a number of improvements over the conventional, qualitative Lumipulse
HBsAg assay: (i) the samples are first processed with a "pretreatment solution" that includes a surfactant to disrupt the HBV particles and linearize HBsAg, and (ii) the antibody conjugated to the ferrite particles was changed from a polyclonal antibody to two monoclonal antibodies (HBs5C3 and HBs163), one against the external structural region as determinant "a", and the other against an internal epitope as a capture reagent.
The sample (100 μL) or calibrator (100 μL) was added to 20 μL of pretreatment solution and mixed. The mixture was added to the HBsAg-HQ ferrite particle reagent (250 μL), and then incubated at 37°C for 10 minutes. The ferrite particles were separated magnetically and washed three times with a washing solution.
The particles were then added to 250 μL of the alkaline phosphatase-conjugated anti-HBsAg antibody reagent and incubated at 37°C for 10 minutes. After the particles were separated and washed, 200 μL of AMPPD was added and the mixture was incubated at 37°C for 5 minutes. The chemiluminescent emission of the mixture was then quantified. This two-step assay was carried out using the automated chemiluminescent enzyme immunoassay instrument, LUMIPULSE G1200. 
| Performance evaluation testing
Within-run reproducibility (n = 10) of the HBsAg-HQ assay was assessed using three serum control panels, as described above, and the mean, SD, and CV were calculated for each panel.
Serum samples with high concentrations of HBsAg, which were obtained from hospitalized patients or outpatients at Osaka University Hospital, were combined to yield a pool containing approximately 160 000 HBsAg IU/mL. This pool was used to prepare a dilution series, based on 2-fold serial dilutions. The HBsAg titers of the dilution series were measured by the Lumipulse HBsAg-HQ assay in order to evaluate reagent performance in terms of dilution linearity.
HBsAg specimens were prepared at 0.0052, 0.0041, 0.0033, 0.0021, 0.0016, 0.0011, 0.0008, 0.0006, and 0 IU/mL, diluted using a solution containing BSA, and HBsAg-HQ testing was performed 20 times using these samples to measure the analytical sensitivity.
Serum samples from 102 HBV-infected patients as described above were tested using the HBsAg-HQ and four commercial HBsAg assay kits. The samples were judged to be positive according to each manufacturer's instructions and assays.
The analytical sensitivities of the five commercial HBsAg assays, including the HBsAg-HQ, were tested against the HBsAg seroconversion panel, PHA935A (SeraCare Life Science, Inc.). Panel PHA935A
consists of serial blood specimens from an individual donor during the seroconversion phase to HBV positivity, and includes specimens before HBsAg is detectable as shown in the technical sheet for PHA935A.
The reactivities of the five commercially available HBsAg assays were tested against the HBsAg subtype panel, PHA807 (SeraCare Life Science, Inc.), which comprises a series of specimens and was diluted using the HBsAg-HQ diluent. Two dilution series of PH807 to the concentration of 0.1 ng/mL of HBsAg, and further dilution by a diluent (indicated as dil. in the Table below) were prepared.
Assessments of samples of wild-type HBsAg and HBsAg with
amino acid substitutions, as described above, were performed. The assay results were expressed in IU/mL and ratio (%) against wild-type antigen as shown in Table 6 .
The specificity study was performed using 1000 serum samples These 12 231 samples were tested and the assay values were distributed into nine groups as follows: less than 0.005, 0.005-0.05, 0.05-0.5, 0.5-5, 5-50, 50-500, 500-5000, 5000-15 000, and greater than 15 000 IU/mL HBsAg. Samples with low levels of HBsAg were retested and/or underwent neutralization testing following the manufacturer's instructions.
Confirmation of positive results from the HBsAg-HQ reagent was carried out using the Lumipulse HBsAg-HQ confirmation reagent. One tenth volume of neutralization solution was added to the specimen (A). As a control, a diluent of 1/10 volume not containing the neutralizing component was added to the specimen (B). Each mixture was left at 20-30°C for 10-60 minutes and the HBsAg-HQ assay was then carried out. When the value of A/B was less than 50%, the test was determined to be positive.
| Data analysis
Parametric methods with minimum two correlations were used for statistical analysis. A two-tailed P-value less than .05 was considered to be statistically significant.
| RESULTS
| Within-run reproducibility and linearity of dilution
Within-run reproducibility values (n = 10) for the HBsAg-HQ assay were 2.55%, 2.31%, and 1.93% as the CVs for the low, middle, and high concentrations of HBsAg, respectively ( Table 2 ). The linearity-ofdilution assessment was performed for diluted HBsAg samples and the results were linear between 0.005 and 150 IU/mL HBsAg. There was no prozone phenomenon ( Figure 1 ).
| Analytical sensitivity against HBsAg assay kits
The LOD calculated by the ±3 SD method was 0.0011 IU/mL (Figure 2 ).
Regarding sensitivity testing, all 102 samples were positive by the (Table 3) .
| The sensitivity of detection of HBsAg during acute HBV infection
For sensitivity testing of the five commercial assays against the HBsAg seroconversion panel (PHA935A), the 14-day blood sample was positive by the HBsAg-HQ assay, the 21-day sample was positive by the ARCHITECT, HISCL, and ADVIA-II assays, and the 23-day sample was positive by the Lumipulse HBsAg (Table 4) .
| Analytical sensitivity against HBV subtypes "ad" and "ay"
The reactivity of the five assays against HBsAg "ad" and "ay" subtypes was 0.025 ng/mL of "ad" and 0.025 ng/mL of "ay" ( Table 5 ). The ARCHITECT, HISCL, and ADVIA-II assays detected 0.2 ng/mL but not 0.1 ng/mL of subtypes "ad" and "ay". The Lumipulse HBsAg assay detected 0.3 ng/mL of "ad" and 0.4 ng/mL of "ay" (Table 5 ).
| Reactivity against HBsAg with amino acid substitutions
The reactivity of the HBsAg-HQ assay against HBsAg variants was evaluated on 22 HBsAg recombinant proteins with one or two amino acid substitutions (Table 6 ). Wild-type HBsAg was used as the con- following the manufacturer's instructions. These three samples showed less than 50% signal reduction, indicating that they were HBsAg negative. The sample judged as positive was described as +, and the specimen judged as negative was done as -. that the values of HBsAg measured in the low range using HBsAg-HQ were clearly higher than those of HISCL and ARCHITECT ( Figure 3A ).
T A B L E 3 Analytical sensitivity against samples obtained from 102 HBV-infected individuals T A B L E 4 Analytical sensitivity against the HBsAg seroconversion panel
In Figure 3B , the ratio of the HBsAg-HQ to HBsAg values of HISCL and ARCHITECT was plotted for each specimen. In each combination, The sample judged as positive was described as +, and the specimen judged as negative was done as -.
| DISCUSSION
There are three HBsAg proteins, small (S), medium (M), and large (L). In addition to the virions, the sera of viremic patients contain 104-to 106-fold more small (S) proteins (spherical and filamentous particles) than infectious Dane particles containing HBV DNA.
From the diagnostic perspective, HBsAg assay reagents should be able to detect all three forms of circulating HBsAg, thereby increasing the probability of identifying infected individuals.
In attempts to achieve greater sensitivity of HBsAg detection, samples have been pretreated and pretreatment was shown to be effective for disrupting several forms of HBsAg. T A B L E 7 Detection specificity of HBV-negative seropanels treatment for hepatitis might be delayed. Therefore, we consider that the significance of finding positive samples in the group considered negative is high. Certainly, the special report "JSH guidelines for the management of hepatitis B virus infection" also says that a high sensitivity testing method should be used for the measurement of HBsAg. Therefore, this assay appears to be a convenient, accurate, and precise test for HBsAg. Furthermore, the highly sensitive HBsAg-HQ assay, which uses a pretreatment step and antibodies against both inner and outer epitopes of the HBsAg molecule, reportedly detected positive results in HBsAg seroclearance cases, which were negative by a conventional HBsAg assay. Anti-HBV therapy and passive-active immunization (hepatitis B immune globulin and HBV vaccine) have been found to select HBsAg variants. 13 Amino acid substitutions within the "a" determinant can lead to conformational changes and several commercially available We think that HBsAg-HQ, which is more sensitive than other HBsAg assays, reduces the number of cases judged as HBV reactivation cases from a previous infection and we can detect reactivation at an earlier stage.
For the latest Hepatitis B treatment guideline (3rd edition, Aug 2017), measurement of HBs DNA is recommended for monitoring in immunosuppressive therapy, and substitution with high sensitivity HBsAg (sensitivity 0.005 IU/mL) should also be considered in accordance with the nature of the treatment.
Actually, in our study, two of the 29 specimens within the range of 0.005-0.05 IU/mL, HBsAg were from HBV carriers that followed de novo hepatitis. De novo hepatitis may simply be unable to detect trace amounts of HBsAg due to the sensitivity of the assay reagent or because co-existing anti-HBs neutralizing antibodies mask HBsAg. More remarkably, 10 out of the 29 cases were judged as positive by the HBsAg-HQ assay for the first time;
it can be said that obviously we reduced the number of cases of de novo hepatitis.
In conclusion, a quantitative HBsAg value is a promising diagnostic tool for monitoring the course of HBV infection prior to or during antiviral therapy, because the elimination of HBsAg (HBsAg seroconversion and/or seroclearance) is the ultimate goal of anti-HBV therapy. Therefore, we think that a highly sensitive HBsAg assay might enable the optimization of management strategies for a considerable proportion of patients with HBV infection.
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